Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hypothyroidism occurs in around 20% or 5-10% of thalidomide- or lenalidomide-treated patients.
“Hypothyroidism occurs in around 20 or 5–10% of thalidomide- or lenalomide-treated patients (57, 58).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [57]
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · see citing works
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · see citing works
Self-citationBarlogie, B., Desikan, R. K., Eddlemon, P., Spencer, T., Zeldis, J. B., Munshi, N. C., Badros, A. Z., Zangari, M., Anaissie, E. J., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 539 · see citing works
Self-citationZangari, M., Anaissie, E. J., Barlogie, B., Badros, A. Z., Desikan, R. K., Gopal, A. V., Morris, C., Toor, A. A., Siegel, E. R., Fink, L. M., et al. (2001) · Blood · doi:10.1182/blood.v98.5.1614 · Cited by 490 · see citing works
Self-citationInterpretation of thyroid function tests
Dayan, C. M. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04060-5 · Cited by 162 · see citing works
Life-Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for Myeloma
Rajkumar, S. V., Gertz, M. A., & Te, W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431315 · Cited by 99 · see citing works
The pattern of a TH1 cytokine in autoimmune thyroiditis
Drugarin, D., Negru, S. M., Koreck, A., et al. (2000) · Immunology Letters · doi:10.1016/s0165-2478(99)00156-x · Cited by 65 · see citing works
Thalidomide hypersensitivity in AIDS
Williams, I., Weller, I. V. D., Malin, A. S., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)91221-f · Cited by 51 · see citing works
Treatment Approaches for Relapsing and Refractory Multiple Myeloma
Esteve, J. (2000) · Acta Oncologica · doi:10.1080/028418600750063604 · Cited by 36 · see citing works
Antithyroid Activity of N-Phthalyl Glutamic Acid Imide (K 17)
Murdoch, J. M., & Campbell, G. D. (1958) · BMJ · doi:10.1136/bmj.1.5062.84 · Cited by 31 · see citing works
Myxoedema after Thalidomide ("Distaval")
Simpson, J. A. (1962) · BMJ · doi:10.1136/bmj.1.5270.55-a · Cited by 18 · see citing works
Myxoedema after Thalidomide ("Distaval")
Lillicrap, D. A. (1962) · BMJ · doi:10.1136/bmj.1.5276.477-a · Cited by 18 · see citing works
Alexander, I. R. W. (1961) · BMJ · doi:10.1136/bmj.2.5264.1434-a · Cited by 10 · see citing works
Nygaard, B., Jarløv, A., Kristensen, L. Ø., et al. (2000) · Hormone and Metabolic Research · doi:10.1055/s-2007-978637 · Cited by 8 · see citing works
Effect of Rubber on Haemoglobin
Raper, A. B. (1957) · BMJ · doi:10.1136/bmj.2.5058.1434-a · Cited by 4 · see citing works
[Clinical studies with a new sedative and hypnotic].
ESSER, H., & Heinzler, F. (1956) · PubMed · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03253.x · Cited by 109 · see citing works
Muller, I., Moran, C., Lecumberri, B., Decallonne, B., Robertson, N., Jones, J., & Dayan, C. M. (2019) · European Thyroid Journal · doi:10.1159/000500881 · Cited by 78 · see citing works
Figaro, M. K., Clayton, W., Usoh, C., Brown, K., Kassim, A., Lakhani, V. T., & Jagasia, S. (2011) · American Journal of Hematology · doi:10.1002/ajh.22008 · Cited by 43 · see citing works
Drugs and Other Substances Interfering with Thyroid Function
Montanelli, L., Benvenga, S., Hegedüs, L., Vitti, P., Latrofa, F., & Duntas, L. H. (2018) · Endocrinology · doi:10.1007/978-3-319-45013-1_27 · Cited by 18 · see citing works
L-T4 therapy in the presence of pharmacological interferents
Benvenga, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607446 · Cited by 13 · see citing works
“Hypothyroidism occurs in around 20 or 5–10% of thalidomide- or lenalomide-treated patients (57, 58).”
Background
- Authors
- Badros, A. Z., Siegel, E., Bodenner, D., Zangari, M., Zeldis, J., Barlogie, B., & Tricot, G.
- Affiliations
- University of Arkansas for Medical Sciences (US)
- Corresponding author
- Badros, Ashraf Z
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2002-04
- Volume
- 112
- Issue
- 5
- Pages
- 412-413
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2111454841
- Cited by
- 83
- References
- 16
- Citations by year
- 2026: 2 · 2024: 2 · 2022: 3 · 2020: 4 · 2019: 1 · 2018: 2 · 2017: 2 · 2015: 4 · 2014: 5 · 2013: 1 · 2012: 3
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- hypothyroidism, thalidomide, multiple myeloma, drug-induced hypothyroidism, thyroid-stimulating hormone, thyroxine, adverse drug reactions, relapsed multiple myeloma, hypothyroidism treatment
- MeSH terms
- Adult, Clinical Trials as Topic, Female, Humans, Hypothyroidism, Male, Middle Aged, Multiple Myeloma, Thalidomide, Thyroid Function Tests, Thyrotropin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
